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NQO1 targeting prodrug triggers innate sensing
to overcome checkpoint blockade resistance
Xiaoguang Li1,2,5, Zhida Liu 1,5, Anli Zhang1, Chuanhui Han1, Aijun Shen1, Lingxiang Jiang3, David A. Boothman4,
Jian Qiao1, Yang Wang1, Xiumei Huang3 & Yang-Xin Fu 1
Lack of proper innate sensing inside tumor microenvironment (TME) limits T cell-targeted
immunotherapy. NAD(P)H:quinone oxidoreductase 1 (NQO1) is highly enriched in multiple
tumor types and has emerged as a promising target for direct tumor-killing. Here, we
demonstrate that NQO1-targeting prodrug β-lapachone triggers tumor-selective innate sen-
sing leading to T cell-dependent tumor control. β-Lapachone is catalyzed and bioactivated by
NQO1 to generate ROS in NQO1high tumor cells triggering oxidative stress and release of the
damage signals for innate sensing. β-Lapachone-induced high mobility group box 1 (HMGB1)
release activates the host TLR4/MyD88/type I interferon pathway and Batf3 dendritic cell-
dependent cross-priming to bridge innate and adaptive immune responses against the tumor.
Furthermore, targeting NQO1 is very potent to trigger innate sensing for T cell re-activation to
overcome checkpoint blockade resistance in well-established tumors. Our study reveals that
targeting NQO1 potently triggers innate sensing within TME that synergizes with immu-
notherapy to overcome adaptive resistance.
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Programmed death 1 (PD-1): Programmed Death-Ligand 1(PD-L1) monoclonal antibodies have demonstrated efﬁca-cious and durable responses across several different cancer
types, and these initial clinical successes have highlighted the ﬁeld
of cancer immunotherapy1,2. Unfortunately, only a minority of
patients treated with anti-PD-1/PD-L1 agents have durable
responses3. While other checkpoints may contribute to low
response and relapse, additional checkpoint blockades on T cells
have not improved response rates4,5. The dysfunctional antigen-
presenting cells (APCs) inside tumor microenvironment might
limit optimal activation of T cells6. While tumor antigens might
be available inside tumor environment, lack of proper antigen
processing and presentation might limit tumor-speciﬁc T cells to
be reactivated.
The generation of effective adaptive immunity requires the
coordinative innate immune response, including sensing of
danger or damage signals to activate innate cells (i.e. dendritic
cells, macrophages, and natural killer cells), antigen processing
and presentation, type I IFN production, and cross-priming of
T cells7. In general, these danger or damage signals are recognized
by extracellular and intracellular pattern recognition receptors
(PRRs) expressed by innate immune cells, and promote the
uptake of antigens, activate APCs, and facilitate the interaction
between APCs and damaged cells8. However, these critical
properties of normal innate immune responses are often cor-
rupted in the tumor microenvironment9. For example, cancers
pervasively favor the survival of tumor clones lacking or unable to
present adequate neo-antigens; tumors also prefer PRRs signals or
dysfunctional innate immune cells that promote cancer inﬂam-
mation rather than priming an adaptive response6,10,11.
Since tumors exhibit impaired innate sensing that favors an
immunosuppressive microenvironment, an important con-
sideration in improving checkpoint blockade is to enhance innate
signals in the tumor microenvironment. One possible approach
to achieve this goal involves the induction of immunogenic cell
death (ICD) within the tumor microenvironment9. For example,
a number of DNA-damaging or DNA repair inhibiting che-
motherapies (such as anthracyclines and oxaliplatin) and radio-
therapy elicit ICD12. ICD is characterized by release of a series of
immunostimulatory damage-associated molecular patterns
(DAMPs) such as high mobility group box 1 (HMGB1) protein,
extracellular ATP, cytoplasmic calreticulin, and endogenous
nucleic acids by the dying tumor cells13. These DAMPs are
recognized by their cognate PRRs expressed by innate immune
cells. This DAMP/PRR signaling alters the inﬂammatory micro-
environment and/or stimulates neoantigen production, and
attracts and activates APCs to activate T cells, which are now
licensed to attack the tumor14. Thus, the immunostimulatory
properties make ICD-inducing agents attractive candidates for
combining with immunotherapy. However, only a few cytotoxic
drugs have been identiﬁed as ICDs inducers, and the general
toxicities, immune suppressive nature, and lack of tumor selec-
tivity limit their use. Thus, it is highly desirable to explore whe-
ther “targeted” agents can more speciﬁcally increase innate
sensing and subsequently expand the beneﬁts of anit-PD-1/PD-
L1 treatment.
NAD(P)H:quinone oxidoreductase 1 (NQO1) is a cytosolic
two-electron oxidoreductase which is upregulated in many
human cancers15,16. High-level expression of NQO1 is associated
with late clinical stage, poor prognosis and lymph node
metastasis17,18. NQO1 bioactivatable drugs, including β-
lapachone (β-lap, in clinical form, ARQ761), have a unique
quinone structure which can be catalyzed by NQO1 to generate
reactive oxygen species (ROS)19. In general, one mole of β-lap
generates ~120 moles of superoxide, consuming ~60 moles of
NAD(P)H in ~2 min20. NQO1 is overexpressed in tumor cells
and catalase, a hydrogen peroxide (H2O2) scavenging enzyme, is
lost in tumor tissues versus normal tissue21. High NQO1:Catalase
ratios in human cancers can offer an optimal therapeutic window
for the use of NQO1 bioactivatable drugs, while low expression
ratios protect normal tissues. The intensive tumor-speciﬁc ROS
production leads to extensive oxidative DNA lesions and tumor
selective cell death22. It has been demonstrated that NQO1
bioactivaible β-lap causes unrepaired DNA damage and cell death
and synergizes with PARP1 inhibitors and radiotherapy in
xenograft models19,23. β-Lap is currently being tested in mono-
therapy or in combination with the other chemodrugs in patients
with NQO1+ solid tumors (ClinicalTrials.gov identiﬁers
NCT02514031 and NCT01502800). However, evaluations of the
antitumor efﬁcacy of β-lap were mainly carried out in vitro and in
immunodeﬁcient mouse models, and improving therapy often
focused on enhanced direct tumor killing with little attention to
adaptive immunity.
Here we screen and identify high NQO1 expression in murine
tumor lines. Using syngeneic or T cell reconstituted human
xenograft mouse models, we report that β-lap-induced tumor
control largely depends on adaptive immunity through tumor-
speciﬁc innate sensing for adaptive immunity leading to tumor
control. Furthermore, targeting NQO1 is very potent to trigger
innate sensing and overcome checkpoint blockade resistance.
Results
β-Lap selectively suppresses NQO1+murine tumor growth. For
years, the evaluations of the antitumor efﬁcacy of β-lap have been
mainly carried out direct killing assay by in vitro assays or in
immunodeﬁcient mouse models. To study whether this prodrug
can trigger immune responses, multiple murine cancer cell lines
were screened to examine the role of NQO1 in β-lap function.
Tumor cell lines (MC38 colorectal adenocarcinoma, TC-1 lung
cancer and Ag104Ld ﬁbrosarcoma) that express a high level of
NQO1 (Supplementary Fig. 1a) were sensitive to β-lap exposure
(Fig. 1a). In contrast, NQO1-deﬁcient cell lines, B16 (melanoma)
and Panc02 (pancreatic cancer) (Supplementary Fig. 1a), were
resistant to β-lap exposure (Fig. 1a). Dicoumarol, an NQO1 spe-
ciﬁc inhibitor, reversed the NQO1-mediated lethality (Fig. 1b).
Next, we determined whether depletion of NQO1 abrogates the
cytotoxicity of β-lap. CRISPR-mediated NQO1 knockout (Sup-
plementary Fig. 1b) endowed MC38 cells resistance to β-lap
treatment (Fig. 1c, Supplementary Fig. 1c). Similarly, over-
expression of NQO1 in B16 cells (Supplementary Fig. 1d) led to
sensitivity to β-lap (Fig. 1d, Supplementary Fig. 1e), and inhibi-
tion of NQO1 by dicoumarol spared β-lap lethality (Supple-
mentary Fig. 1f). Lethal dose of β-lap caused rapid cell swelling,
membrane rupture, and Annexin V+/7AAD+ cell death (Fig. 1e).
NQO1 catalyzes the two-electron oxidoreduction of β-lap to
generate high levels of ROS (i.e. hydrogen peroxide/H2O2),
causing massive DNA oxidation and cell death19. Indeed, β-lap
induced high level of ROS in NQO1-positive murine tumor lines
and much less in NQO1-null lines (Fig. 1f, g). Inhibition of
NQO1 by dicoumarol abolished this effect (Fig. 1f, g). Next, we
determined whether neutralizing ROS could inhibit β-lap-
induced cell lethality. Catalase, an H2O2 scavenging enzyme,
signiﬁcantly spared β-lap-mediated lethality (Fig. 1h, Supple-
mentary Fig. 1g). These results suggest that β-lap induces NQO1+
tumor cell death through intensive tumor-speciﬁc ROS produc-
tion in vitro.
We further examined the antitumor efﬁcacy of β-lap in three
subcutaneous syngeneic tumor models: MC38, TC-1, and B16 each
with different NQO1 levels. In the MC38 tumor model, 25mg/kg of
β-lap was systemically (intravenously) administered to tumor-
bearing WT C57BL/6 mice on day 7 after tumor inoculation.
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Fig. 1 β-Lap kills murine tumor cells in an NQO1-dependent manner. a NQO1 positive tumor cell lines MC38, TC-1, and Ag104Ld and NQO1 negative cell
lines Panc02 and B16 grown in 96-well plates were treated with β-lap (0–6 μM) for a 3 h followed by washing and replacing medium. Cell viability was
determined by Sulforhodamine B (SRB) Assay 48 h later. b MC38, TC-1 and Ag104Ld cells were exposed to 4 μM β-lap ± dicoumarol (DIC, 50 μM) for 3 h
and cell survival was assessed 48 h later. c MC38 cells with CRISPR-based NQO1 knockout (MC38 NQO1KO #5) planted in 96-well plates were exposed
to β-lap for 3 h and cell survival was assessed 48 h later. d B16 cells stalely harboring a pCMV-NQO1 expression vector (B16 NQO1#1) planted in 96-well
plates were exposed to β-lap ± dicoumarol (DIC, 50 μM) for 3 h purse and survival assessed 48 h later. eMC38 cells were exposed to a lethal dose of β-lap
(4 μM) for indicated times, then stained with 7AAD and Annexin V followed by ﬂow cytometry analysis. f, g MC38 cells in f or B16 and B16 NQO1#1 cells
in g were exposed to β-lap ± dicoumarol (DIC, 50 μM) for 3 h and then ROS level was determined by DCFDA cellular ROS assay. h MC38 and B16
NQO1#1 cells were exposed to β-lap for 3 h. Catalase (1000 U/ml) was added and cell survival was assessed 48 h later. i C57BL/6 mice (n= 5/group)
were transplanted with 6 × 105 MC38 cells and treated with β-lap (1.5, 5, or 15 mg/kg, intratumorally; or 25 mg/kg, i.v.) every other day for four times.
j C57BL/6 mice were transplanted with 6 × 105 MC38 cells (NQO1 WT or KO, n= 5/group) and treated with β-lap (15 mg/kg, i.t.) every other day for four
times. Data are shown as mean ± SEM from three independent experiments. **p < 0.01, ***p < 0.001, ****p < 0.0001 determined by unpaired Student's
t-test in f– h or two-way ANOVA in i and j
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Treatment with β-lap resulted in marked tumor inhibition (Fig. 1i).
β-Lap might act on various cells when delivered systemically. To
mechanismically explore whether and how β-lap functions within
the local tumor environment for tumor regression, various doses of
β-lap were intratumorally injected every other day for total four
doses. Local treatment also signiﬁcantly suppressed tumor growth
in a dose-dependent manner. Tumor growth inhibition rates (TGI,
%) were 62.5% for mice with systemic β-lap treatment and 11.8%,
69.4%, and 89.3% for mice with local β-lap (1.5 mg/kg, 5 mg/kg, and
15mg/kg) treatments (Fig. 1i). Notably, local treatment with much
lower dose of β-lap (15mg/kg) induced more robust tumor
regression than systemic treatment and 46.7% (7/15) of mice
achieved complete tumor rejection (Fig. 1i), suggesting that major
action site might be related to local tumor microenvironment.
Moreover, β-lap treatment dramatically increased the ratio of
Annexin V+/7AAD+ and Annexin V+/7AAD− (Supplementary
Fig. 1h) and decreased the Ki-67+ populations (Supplementary
Fig. 1i) in CD45-negative cells, indicating the cytotoxicity of β-lap
on tumor cells in vivo. Consistent with the in vitro study, β-lap’s
therapeutic effect was abolished in NQO1 knockout MC38 mouse
models. (Fig. 1j). Similarly, in TC-1 tumor model, β-lap treatment
also led to signiﬁcant tumor suppression (Supplementary Fig. 1j).
To further conﬁrm the speciﬁcity of β-lap in vivo, we established
subcutaneous xenografts using parental NQO1-deﬁcient or NQO1-
overexpressing B16 cells clone (#1 and #4) in WT C57BL/6 WT
mice. As expected, NQO1-null tumors did not respond to β-lap
treatment (Supplementary Fig. 1k). In sharp contrast, NQO1
overexpressing (clone #1 and #4) tumor-bearing mice showed a
dramatic tumor suppression after β-lap treatment (Supplementary
Fig. 1k). Of note, B16 tumors overexpressing NQO1 grew much
faster than B16 parent cells, indicating that NQO1 promotes in vivo
tumor growth16. Together, these results provide evidence that β-lap
selectively suppresses NQO1 positive murine tumor growth in vitro
and in vivo; NQO1 is essential and sufﬁcient for β-lap-mediated
antitumor effect.
β-Lap-mediated-antitumor effect depends on CD8+ T cells.
Most studies on how β-lap kills tumor cells have focused on
cancer cell-autonomous mechanism19,20,23. Here, we asked
whether β-lap-mediated antitumor effect involves the immune
system. We established MC38 tumors in immunocompetent and
immunodeﬁcient mice respectively to study the effect of β-lap on
adaptive immunity. After only four doses of β-lap treatment,
MC38 tumor was eradicated in WT C57BL/6 mice with 50% of
mice cured (Fig. 2a). Unexpectedly, β-lap lost therapeutic activity
in immune-deﬁcient Rag1 KO (Rag1−/−) C57BL/6 mice (Fig. 2a).
A similar effect was observed in NQO1 overexpressing B16 tumor
model (Supplementary Fig. 2a), suggesting that the adaptive
immune system is required for the profound antitumor effect of
β-lap in vivo. Indeed, we found an increase in CD4+ and CD8+
T cells in β-lap-treated tumors compared to control MC38
tumors (Supplementary Fig. 2b), suggesting that some subsets of
T cells might contribute to adaptive immunity. While treatment
with β-lap alone or β-lap combined with CD4+ T cell depletion
controlled MC38 tumor growth, CD8+ T cells depletion abol-
ished β-lap’s antitumor effect (Fig. 2b, Supplementary Fig. 2c),
suggesting that CD8+ T cells, but not CD4+ T cells, are required
for β-lap-mediated tumor regression. Similar results were
obtained in mice bearing TC-1 tumors (Fig. 2c). To determine
whether β-lap-mediated antitumor responses result in prolonged
protective T cell immunity, we rechallenged the mice that
underwent complete MC38 tumor rejection after β-lap treatment
with a lethal dose of MC38 cells. All the β-lap cured mice rejected
the rechallenged tumors (Fig. 2d), indicating the generation of
memory T cells after β-lap treatment
To test the efﬁcacy of β-lap in controlling human tumors, we
developed two xenograft models in immune-reconstituted
C57BL/6 Rag1−/− (Fig. 2e) and NSG-SGM3 mice (Fig. 2f).
Human lung carcinoma cell line A549 that highly expresses
NQO1 was sensitive to β-lap treatment in vitro (Supplementary
Fig. 2d). In C57BL/6 Rag1−/− immune-reconstituted model6,24,
A549 cells were s.c. inoculated. After the tumor was well
established (about 100 mm3), a total of 2 × 106 lymph node
(LN) cells from OTI transgenic mice were transferred into tumor-
bearing Rag1−/− mice to reconstitute a small number of T cells
without reducing tumor growth. LN cells from OTI transgenic
mice contain about 98% OVA- speciﬁc T cell that cannot respond
to human tumor antigens but suppress homeostatic proliferation
of a small number of non-OTI T cells. A small fraction of non-
OT-1 T cells have the potential to recognize human tumor
antigens, which approximates 200–1000 clones, the number of
tumor-reactive T cell in human patients. Without T cell transfer,
β-lap treatment only partially inhibited A549 tumor growth.
However, in the presence of T cells, β-lap induced more robust
tumor regression with 50% of tumors completely rejected
(Fig. 2e), indicating that β-lap-mediated antitumor effects are
largely dependent on T cells. To study the T cell function in β-
lap-mediated tumor suppression in a human-speciﬁc system, we
further developed a next-generation humanized xenograft model
with NSG-SGM3 mice25. NSG-SGM3 mice injected with human
CD34+ hematopoietic stem cells (Hu-NSG-SGM3) showed a
robust engraftment efﬁciencies measured by ﬂow cytometry using
human CD45, CD3, CD4, and CD8 leukocyte markers (Supple-
mentary Fig. 3a). Naïve NSG-SGM3 and Hu-NSG-SGM3 mice
were separately inoculated with A549 cells and were treated with
β-lap. In line with a murine syngeneic model, β-lap had a limited
antitumor effect in A549-bearing immune-deﬁcient NSG-SMG3
mice (Fig. 2f). Notably, in the presence of the human immune
system, β-lap treatment induced profound tumor regression,
indicating that the reconstituted immune system restored the
antitumor effect of β-lap (Fig. 2f). We further investigated tumor-
inﬁltrated immune cells in the tumor microenvironment, and
found a signiﬁcant increase of CD45+ cells, and CD8+ T cells but
not CD4+ T cells in the tumor tissues after β-lap treatment
(Supplementary Fig. 3b). Together, these data reveal the necessity
of T cells in β-lap-induced tumor control.
β-Lap induces dendritic cell-mediated T cell cross-priming.
Given that CD8+ T cells are essential for the antitumor efﬁcacy of
β-lap, we hypothesized that β-lap treatment increases the antigen-
speciﬁc T cell response. To rule out of direct effect of β-lap on
CD8+ T cells, we evaluated the expression of NQO1 on CD8+
T cells and the effect of β-lap on CD8+ T cell survival, pro-
liferation, and function. The results showed that neither naive
CD8+ T from spleen nor tumor-inﬁltrating CD8+ T cell
expressed NQO1 (Supplementary Fig. 4a). Moreover, tumor
lethal dose of β-lap had no effect on CD8+ T cell apoptosis and
on anti-CD3/anti-CD28-stimulated cell proliferation and IFNγ
production (Supplementary Fig. 4b–d). To test if β-lap increases
the antigen-speciﬁc T cell response, splenocytes from MC38
tumor-bearing mice were collected 10 days after the initial β-lap
treatment and an IFNγ ELISPOT assay was performed to mea-
sure the effector function of activated T cells. As shown, in the
presence of tumor antigen (irradiated tumor cells), IFNγ-
producing T cells dramatically increased in the β-lap treatment
group (Fig. 3a). We further generated an MC38-OVA cell line
using OTI peptide to better track T cell responses. Similarly, in
the IFNγ ELISPOT assay with OTI peptide, the numbers of OTI-
speciﬁc T cells were much higher in spleens of mice after β-lap
treatment (Fig. 3b). The increase of tumor-speciﬁc CD8 cells
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suggests that β-lap treatment might induce cross-priming and
reactivate T cells to control the tumor growth. Cross-presentation
by APCs such as dendritic cells (DCs) or macrophages is con-
sidered the major priming mechanism to activate tumor-speciﬁc
T cells. To further nail down which APCs are essential for β-lap-
induced antitumor effect, we ﬁrst used anti-CSF1R Ab to deplete
macrophages in the tumor tissue26. As shown, macrophage
depletion did not affect the response of MC38-bearing mice to β-lap
treatment (Fig. 3c). Batf3-dependent DCs (CD8α+ or CD103+
DCs) specialize in cross-presentation of necrotic tumor cell-derived
epitopes to directly activate CD8+ T cells27–29. Batf3−/− mice lack
functional CD8α+ or CD103+ DCs and have impaired cell cross-
presentation activity. In WT mice, β-lap treatment induced a robust
tumor regression (Fig. 3c). In stark contrast, no therapeutic effect
was seen in identically treated Batf3−/− mice (Fig. 3d). To further
address the possibility that β-lap could increase cross-presentation,
we used an antigen-speciﬁc system to track the priming and acti-
vation of tumor antigen-speciﬁc T cells. WT mice bearing MC38-
OVA tumors were treated with β-lap, then DCs were isolated from
the tumor-drain lymph nodes (TdLN) and co-cultured with CD8+
T cells from OTI transgenic mice. IFNγ secretion was measured to
evaluate the capability of DCs to prime the antigen-speciﬁc T cells.
Indeed, after β-lap treatment, DCs induced more IFNγ production
by OTI T cells (Fig. 3e). Together, these results suggest that
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Fig. 2 β-Lap-mediated-antitumor effect depends on CD8+ T cells. a 6 × 105 MC38 cells were subcutaneously transplanted into C57BL/6 WT (n= 5 for
vehicle group; n= 6 for β-lap treatment group) and Rag1−/− mice (n= 5/group), respectively. Tumor-bearing mice were treated with β-lap (15 mg/kg, i.t.)
every other day for four times. Numbers of tumor-free mice after treatment were shown. b C57BL/6 mice (n= 5/group) were transplanted with 6 × 105
MC38 tumor and treated with β-lap (15 mg/kg, i.t.) every other day for four times. For CD8+ T cell depletion, 200 μg of anti-CD8 antibodies were
intraperitoneally injected four times at three days interval during the treatment. c C57BL/6 mice were transplanted with 1.5 × 105 TC-1 tumor cells and
were treated with β-lap (5 mg/kg, i.t.) for four times with or without anti-CD8 antibodies (n= 5 for β-lap treatment group; n= 4 for vehicle, vehicle+
αCD8, and β-lap+ αCD8 groups). d Naïve (n= 5/group) and β-lap cured MC38 tumor-free (n= 7/group) C57BL/6 mice were rechallenged
subcutaneously with 3 × 106 MC38 cells on the opposite site from the primary tumor 30 days after complete rejection, and tumor growth curve was
monitored. e 2 × 106 A549 cells were subcutaneously injected into C57BL/6 Rag1−/− mice (n= 5 for vehicle and β-lap groups; n= 6 for vehicle+OTI
group; n= 7 for β-lap+OTI group). Thirty days later, the mice were i.v. adoptively transfected with 2 × 106 lymph node cells from OT-1 transgenic mice.
On the following day, tumor-bearing mice were intratumorally treated with β-lap (10mg/kg) every other day for four times. f 2 × 106 A549 cells were
subcutaneously injected into NSG-SGM3 (n= 5/group) or NSG-SGM3 harboring human CD34+ hematopoietic stem cells (n= 5 for Hu-NSG vehicle
group; n= 6 for Hu-NSG β-lap group). Tumor-bearing mice were treated with β-lap (10mg/kg, i.t.) every other day for four times. Tumor growth was
measured twice a week. Data are shown as mean ± SEM from three independent experiments. **p < 0.01, ****p < 0.0001 determined by unpaired Student's
t-test in a and b, or two-way ANOVA in c–f
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DC-mediated cross-priming is required for the β-lap-induced
tumor regression and tumor reactive T cell response.
β-Lap-mediated-antitumor effect depends on innate sensing.
APCs in the tumor microenvironment are dysfunctional, leading
to ineffective priming and activation of T cells6,30. Type I inter-
feron (IFN) is essential for optimal cross-priming of T cells30,31.
We tried to determine whether type I IFN signaling was involved
in T cell response mediated by β-lap treatment. Indeed, we
observed upregulated IFNα/β and IFNs response genes CXCL10
as well as other cytokines such as IFNγ and TNFα in tumors
treated with β-lap (Supplementary Fig. 5a, b). We further
examined whether type I IFN signaling was required for the
therapeutic effect of β-lap. Strikingly, blocking type I IFN sig-
niﬁcantly diminished the therapeutic effect of β-lap (Fig. 4a). To
determine whether tumor cell or host IFN signaling was essential,
MC38 tumors were inoculated into WT and IFNAR1-deﬁcient
(Ifnαr−/−) C57BL/6 mice, followed by β-lap treatment. The
results showed that the therapeutic effect was abrogated in mice
with impaired IFNAR1 signaling (Fig. 4b), suggesting that host
type I IFNs are required for β-lap-mediated antitumor effect. It
has been demonstrated that MyD88 is involved in type I IFN
production and antitumor immunity by some anticancer
agents13,32,33. Co-culture of bone marrow-derived dendritic cells
(BMDCs) and β-lap-treated tumor cells (MC38 and NQO1
overexpressing B16 cells) in vitro signiﬁcantly increased the
production of IFNβ protein (Fig. 4c, Supplementary Fig. 5c).
MyD88 deﬁciency completely abolished the IFNβ production
when co-culture β-lap-treated tumor cells with BMDCs from
Myd88−/− mice (Fig. 4c, Supplementary Fig. 5c). To further
determine whether MyD88 signaling is required for β-lap treat-
ment, MC38 tumors cells were s.c. implanted into WT and
MyD88-deﬁcient (Myd88−/−) mice. Similarly, β-lap treatment
increased the level of IFNβ in the tumor tissue in WT but not in
Myd88−/− mice (Fig. 4d). Moreover, β-lap-induced tumor
regression disappeared in MC38 bearingMyd88−/− mice with the
same therapeutic schema (Fig. 4e, Supplementary Fig. 6a). Simi-
larly, the antitumor effect of β-lap in NQO1-overexpressing B16
tumor models was also abolished in Myd88−/− mice (Supple-
mentary Fig. 6b) or Ifnαr−/−mice (Supplementary Fig. 6c). These
results demonstrated that the host MyD88 was indispensable for
the β-lap induced production of type I IFNs and its antitumor
effect.
Because β-lap can induce robust tumor cell death, we
hypothesized that this in turn resulted in the secretion of DAMPs
and exposure of tumor antigens, thereby boosting antitumor
immune responses. Interestingly, knockout of TLR4 but not TLR9,
both of which are the major upstream receptors of MyD88 signaling
to sense the DAMPs, led to the similar therapeutic resistance
(Fig. 4f, Supplementary Fig. 6a). Previous studies have shown that
HMGB1 (and HMGB1/DNA complexes), one of the endogenous
ligands of TLR4, can function as a danger signal that stimulates
DCs cross-priming in a MyD88-dependent fashion33. To determine
whether β-lap-induced tumor regression is HMGB1-dependent,
anti-HMGB1 mAb was administered to neutralize free HMGB1
along with β-lap treatment. The results showed that blockade of
HMGB1 signaling diminished the antitumor effect of β-lap (Fig. 4g),
indicating that β-lap may induce HMGB1 release in the tumor
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microenvironment to enhance innate response via a TLR4/MyD88
pathway. To further address the essential role of HMGB1, we
evaluated the tumor-speciﬁc T cell response when blocking
signaling in conjunction with β-lap treatment. MC38 tumor cells
were s.c. implanted into WT or Tlr4−/− or Myd88−/− C57BL/6
mice, and tumor-bearing mice were treated with β-lap with or
without anti-HMGB1Ab. In WT mice, β-lap treatment increased
the number of tumor-reactive T cells and this effect was abolished
when co-administrated with anti-HMGB1 neutralizing Ab (Fig. 4h).
Similarly, in Tlr4−/− and Myd88−/− mice there were much less
tumor reactive T cells in the control group compared with that in
WT mice (Fig. 4h). More importantly, β-lap treatment could not
enhance the tumor-speciﬁc T cell response in these deﬁcient mice
(Fig. 4h). These results together suggest that the TLR4/MyD88/type
I IFNs signaling cascade is required for β-lap induced innate and
adaptive antitumor immune response.
β-Lap induces HMGB1-dependent tumor ICD. The HMGB1-
dependent tumor-speciﬁc T cell response and HMGB1-
dependent antitumor effect of β-lap in vivo suggested that β-lap
could potentially induce ICD in the tumor. To test this hypoth-
esis, we checked the ICD hallmark: HMGB1 secretion in β-lap-
treated tumor cells in vitro. Indeed, we observed a dose-
dependent secretion of HMGB1 in NQO1+ tumor cells but not
in NQO1− cells (Fig. 5a). Inhibition of NQO1 by dicoumarol
abolished β-lap-induced HMGB1 secretion. We presumed that
HMGB1 exposure might dictate the immunogenicity of β-lap-
induced tumor cell death. HMGB1 was found to be critical for β-
lap-induced immunogenicity in three experiments: (i) BMDCs
were exposed to OVA protein for 4 h, then naïve OT1 CD8+
T cells and the supernatants from β-lap-treated tumor cells (with/
without αHMGB1 antibody or knockdown the HMGB1 in MC38
cells). IFNγ secretion was measured to evaluate the capability of
BMDCs to prime the antigen-speciﬁc T cells. The results showed
that β-lap treatment greatly increased the IFNγ secretion, and this
effect was signiﬁcantly diminished when HMGB1 was neutralized
or knocked down (Supplementary Fig. 7a, b). (ii) Dying MC38-
OVA cells induced by β-lap in vitro were injected into the ﬂank of
C57BL/6 mice in conjunction with or without anti-HMGB1Ab
(Fig. 5b). The numbers of tumor antigen-speciﬁc T cells (Fig. 5c)
and IFNγ production (Fig. 5d) in TdLN were determined; (iii)
C57BL/6 mice that received vaccination with β-lap-induced dying
MC38-OVA cells in the presence of anti-HMGB1Ab were
rechallenged with MC38-OVA for evaluation of the antitumor
protection (Fig. 5e, f). As shown, mice vaccinated with β-lap-
induced dying cells had more IFNγ-producing antigen-speciﬁc
T cells compared to mice vaccinated with living cells (Fig. 5c, d).
However, the tumor-speciﬁc T cell responses diminished when
vaccinated with dying cell and anti-HMGB1Ab mixture (Fig. 5c,
d). Consistently, Tlr4−/− mice also showed reduced tumor
reactive T cells and IFNγ production compared with WT mice
when vaccinated with the identical dying cells (Fig. 5c, d). To test
the ability of β-lap-induced dying cells to activate the adaptive
immune system, we used a prophylactic tumor vaccination model
in immunocompetent C57BL/6 mice (Fig. 5e). Immunization of
mice with β-lap-induced dying cells prevented the growth of the
rechallanged tumor (Fig. 5f). Notably, the antitumor protection
effect decreased when mice were vaccinated with dying cells and
anti-HMGB1 neutralized antibody (Fig. 5f). Together, these
results indicate that β-lap induces ICD and enhances antitumor
immunogenicity in an HMGB1-dependent manner.
β-Lap overcomes checkpoint blockade resistance. In clinical
practice, patients with well-established tumors may generate
complicated immunosuppressive networks and are generally
refractory to immunotherapy3,34. Similarly, in our preclinical
model, complete tumor rejection was achieved only in mice
bearing small tumors (about 50 mm3) after β-lap treatment
(TGI, 93.0%; Fig. 6a, b), and large established tumors (about
150–200 mm3) were only partially controlled by identical
treatment protocols (TGI, 59.36%; Fig. 6a, b). The ﬁnding that
β-lap provokes an innate and adaptive immune response as
part of its mechanism of action paved a path for the combi-
nation of β-lap with T cell checkpoint blockade to eradicate the
advanced and checkpoint blockade refractory tumors. To test
this, we next combined local β-lap treatment with anti-PD-L1
treatment in mice bearing established large MC38 tumors. The
advanced MC38 tumors only showed a moderate response to
anti-PD-L1 alone (TGI, 63.25%; Fig. 6c). In stark contrast,
mice in the combination groups showed robust tumor control
and regression (TGI, 96.86%; Fig. 6c, Supplementary Fig. 8a).
Notably, 60% of tumor-bearing mice completely rejected their
tumors on combination treatment (Fig. 6c, Supplementary
Fig. 8a). Interestingly, synergistic effects of β-lap and immu-
notherapy were also observed using a much lower dose (5 mg/
kg, i.t.) of β-lap locally (Supplementary Fig. 8b). Recent studies
showed that cancer immunotherapy is enhanced by local and
abrogated by systemic chemotherapy treatment35,36. To further
evaluate if systemic β-lap treatment has any immunosuppres-
sive effects and impairs anti-PD-L1 immunotherapy, MC38
tumor-bearing mice were administrated with systemic β-lap
treatment (30 mg/kg, i.p.) monotherapy or combined with
anti-PD-L1 (Fig. 6d). Monotherapy of β-lap or anti-PD-L1 led
to similarly moderate inhibition of tumor growth (Fig. 6e,
Supplementary Fig. 8c). Combination treatment had a syner-
gistic effect on their antitumor action with 25% of tumors
completely rejected (Fig. 6e, Supplementary Fig. 8c) and
markedly improved the survival of tumor-bearing mice
(Fig. 6f). B16 tumors express PD-L1 but have poor immuno-
genicity and are not responsive to PD-L1/PD-1 immune
checkpoint blockade37,38. We used the NQO1-overexpressing
B16 tumor model to evaluate the therapeutic efﬁcacy of β-lap
and anti-PD-L1 combination treatment (Supplementary
Fig. 8e). As expected, NQO1-overexpressing B16 tumors failed
to respond to anti-PD-L1 Ab alone (Supplementary Fig. 8f). By
contrast, β-lap monotherapy largely inhibited the growth of the
B16 NQO1 tumors. Strikingly, when combined with PD-L1
blockade, β-lap had a markedly synergetic antitumor effect
(Supplementary Fig. 8f).
To further elucidate the mechanism of synergy between β-lap
and PD-L1 blockade, we investigated tumor-inﬁltrated immune
cells in the tumor microenvironment by ﬂow cytometry analysis
and tracked antigen-speciﬁc T cells in the MC38-OVA tumor
model. We found a signiﬁcant increase of CD45+ cells, CD8+
T cells, and CD8/Treg ratio in the tumor tissues with either β-lap
or anti-PD-L1 monotherapy, and these effects were dramatically
magniﬁed in the combination group (Fig. 6g). Immunostaining of
CD8+ T cells further conﬁrmed the increased tumor-inﬁltrating
CD8+ T cells in TME (Supplementary Fig. 9). We further tracked
CD8+ T cells speciﬁc for the model antigen OVA257–264 (OTI
peptide) in the tumor tissues and spleen. As shown, either β-lap
or anti-PD-L1 monotherapy increased the OT1 antigen-speciﬁc
T cells in the tumor tissues (Fig. 6g) and spleen (Fig. 6h).
Strikingly, combined therapy robustly expanded the tumor
antigen-speciﬁc T cells (Fig. 6g, h). These results suggest that β-
lap treatment enhanced the tumor immunogenicity and increased
T cell inﬁltration and tumor-speciﬁc T cell response when
combined with the PD-L1 blockade. Taken together, these data
demonstrate a potent synergy between β-lap and PD-L1 blockade
in controlling large established and checkpoint blockade
refractory NQO1-positive tumors.
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Discussion
Lack of proper innate sensing may limit T cell-targeted
immunotherapy9,39,40. We hypothesized that induction of
immunogenic innate sensing via some tumor-targeting genotoxic
agents might induce antitumor immunity and overcome immune
checkpoint blockade resistance. Here we used several syngeneic
immunocompetent mouse models and immune-reconstituted
human xenograft models to evaluate the antitumor efﬁcacy of
NQO1 bioactivatable β-lapachone (β-lap). We demonstrated that
β-lap had an impressive antitumor effect in vivo, largely
depending on innate and adaptive immunity. We discovered that
after activation by NQO1, β-lap caused tumor-selective cell death
and induced innate sensing for adaptive antitumor immunity.
Mechanistically, tumor cells treated with β-lap triggered ICD and
increased tumor immunogenicity by the release of HMGB1. This
activated the innate immune response and induced a type I IFN
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Fig. 6 β-Lap overcomes therapeutic PD-L1/PD-1 blockade resistance. a Treatment schema for local β-lap treatment-based combinative therapy in panel
b and panel c. b, c 6 × 105 MC38 tumor cells were s.c.inoculated into the ﬂank of C57BL/6 mice (n= 5/group). Mice bearing small tumor (about 50mm3,
in b) or advanced tumor (about 150–200mm3, in c) were locally treated with β-lap (15 mg/kg, i.t.) for four times with or without anti-PD-L1-based
checkpoint blockage. Tumor growth was monitored twice a week, and numbers of tumor-free mice after treatment were shown. d Treatment schema for
systemically β-lap treatment-based combinative therapy in panels e and f. e 6 × 105 MC38 tumor cells were s.c. inoculated into the ﬂank of C57BL/6 mice
(n= 5 for vehicle treatment group; n= 6 for β-lap and vehicle+ αPD-L1 groups; n= 8 for β-lap+ αPD-L1 treatment group). Tumor-bearing mice (about
50–100mm3) were systemically treated with β-lap (30mg/kg, i.p.) for six times with or without anti-PD-L1-based checkpoint blockade. Tumor growth was
monitored twice a week, and numbers of tumor-free mice after treatment were shown. f Survival curve for MC38 tumor-bearing mice with combinative
treatment in panel e. g, h C57BL/6 mice bearing MC38-OVA tumor (about 150mm3, n= 4/group) were locally treated with β-lap (15 mg/kg, i.t.) every
other day for four times or anti-PD-L1 (100 μg, i.p.) for three times, alone or combination. Twelve days after ﬁrst treatment, tumor-inﬁltrating CD45+ cells
and lymphocytes were analyzed by ﬂow cytometry in g, and OT-1 antigen-speciﬁc T cells in the spleen were determined by IFNγ ELISPOT assay in h. Data
are shown as mean ± SEM from two to three independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 determined by two-way ANOVA
in b, c, e, g and h or log-rank test in f
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signature in TLR4/MyD88-dependent manner, which stimulated
antitumor T cell adaptive immunity and restrained tumor growth.
Importantly, β-lap overcame immunotherapy resistance. When
combined with anti-PD-L1 mAbs, β-lap further enhanced CD8+
T cell inﬁltration and antigen-speciﬁc T cell response and era-
dicated large established and checkpoint blockade refractory
tumors.
In preclinical and clinical studies, checkpoint blockade essen-
tially takes the “brakes” off the immune system and has proven
insufﬁcient to break tolerance, unless co-administered with cer-
tain “fuels” to activate local immune activities and induce desired
T cell responses29,41,42. Stimulating the innate immune sensing in
combination with T cell checkpoint immunotherapy might be
one answer. One approach to induce immunogenic innate sen-
sing and reshape the tumor microenvironment is to use genotoxic
agents such as chemotherapies that are already widely employed
in cancer treatment9,43,44. Indeed, combining immune checkpoint
blockade with chemotherapy is being extensively studied in
clinical trials12,45–47. However, one of the major limitations in the
use of traditional chemotherapy drugs arises from their lack of
selectivity and related adverse toxicity to non-targeted tissues,
especially the adaptive immune system. NQO1 is a two-electron
oxidoreductase expressed in multiple tumor types at levels 5- to
200- fold above normal tissues, and is a potential therapeutic
target19,23. β-Lap is a new class of NQO1-targeted prodrug which
can be catalyzed and bioactivated by NQO1 to generate ROS19,21.
Indeed, we found that β-lap selectively killed tumors highly
expressing NQO1 both in vitro and in vivo, and this killing effect
was abolished when we knocked out NQO1, indicating the ideal
selectivity of this drug. Although genotoxic agents were assumed
to exert their effects mostly via cancer cell-autonomous
mechanisms for a long time, i.e., by directly inhibiting the pro-
liferation or triggering the demise of malignant cells, accumu-
lating evidence indicates that multiple chemotherapeutics that
have been successfully employed in the clinic for decades also
trigger ICD and elicit anticancer immune responses13. Unfortu-
nately, most ICD-inducing agents have severe side effects at
therapeutic doses due to lack of tumor-selectivity and severe
immunosuppression. Importantly, β-lap distinguished itself from
other chemotherapeutic agents out of its ideal target effect on
NQO1-overexpressing tumors and no immunosuppression on
cytotoxic immunity. We proved that tumor-inﬁltrated CD8+ T
cell lack NQO1 and that β-lap has no cytotoxic effect on native
and activated CD8+ T cell even at the tumor-lethal dose. A cri-
tical question is whether β-lap-mediated tumor-speciﬁc cell death
has some interaction with the immune system; whether this
“targeted” prodrug evokes an ICD and triggers innate sensing.
Currently, we found that β-lap-induced NQO1+ tumor regres-
sion largely depends on host CD8+ T cells. We further proved
that ß-lap induced ICD and activated innate sensing via an
HMGB1/TLR4 pathway and upregulated the type I IFNs signal-
ing in the tumor microenvironment, resulting in the promotion
of Batf3 DCs to cross-prime T cells and activate of antitumoral
adaptive immune response.
Reducing tumor burden and increasing tumor immunogenicity
are believed to be two key factors to improve immunotherapy48.
Notably, β-lap promoted HMGB1-depedent immunogenicity and
activated innate sensing to bridge innate and adaptive immune
response, and markedly shrunk the tumor mass, and is thus a
promising partner for combination with immunotherapy.
Encouragingly, PD-1/PD-L1 blockade has shown promising
capacity to increase the proliferation and function of tumor-
inﬁltrating CD8+ T cells, and enhance the antitumor efﬁcacy in
several cancer types49–52. Indeed, we demonstrated that β-lap
managed to eradicate large established and checkpoint blockade
refractory MC38 and B16 tumors by combination with anti-PD-
L1 immunotherapy and dramatically increased the survival rate.
We further proved that combination therapy dramatically
increased the tumor-inﬁltrating lymphocytes and tumor-antigen-
speciﬁc T cells as well as the CD8/Treg ratio in the tumor
microenvironment, as compared to β-lap or anti-PD-L1
monotherapy.
Overall, our study has provided an insight into how β-lap, a
unique targeted prodrug, induces antitumor effect through
coordinative innate and adaptive immunity and how β-lap
treatment trigger innate sensing for better immunotherapy.
NQO1 can be important biomarker since NQO1 is essential and
sufﬁcient for β-lap-mediated speciﬁc innate sensing and adaptive
T cell responses. β-lap is currently being tested in monotherapy
or in combination with the other chemodrugs in patients with
NQO1+ solid tumors. Our study points out that β-lap’s innate
sensing capability can prepare NQO1+ patients for a successful
response to immunotherapy.
Methods
Mice. Female C57BL/6J and Rag1−/− mice were purchased from UT southwestern
mice breeding core. Myd88−/−, Tlr4−/−, Tlr9−/−, Batf3−/−, and OT1 CD8+ T cell
receptor (TCR)-Tg mice in the C57BL/6J background and NSG-SMG3 mice were
purchased from The Jackson Laboratory. Ifnαr1−/− mice were provided by Dr.
Anita Chong from the University of Chicago. All the mice were maintained under
speciﬁc pathogen-free conditions. Animal care and experiments were carried out
under institutional and National Institutes of Health protocol and guidelines. This
study has been approved by the Institutional Animal Care and Use Committee of
the University of Texas Southwestern Medical Center.
Cell lines and reagents. MC38, B16, Panc02, Ag104Ld, and A549 cells were
purchased from ATCC. TC-1 cells were kindly provided by Dr. T.C. Wu at John
Hopkins University. All cell lines were routinely tested using mycoplasma con-
tamination kit (R&D) and cultured in Dulbecco's modiﬁed Eagle's medium or
RPMI 1640 medium supplemented with 10% heat-inactivated fetal bovine serum,
100 U/ml penicillin, and 100 U/ml streptomycin under 5% CO2 at 37 °C. β-
Lapachone was synthesized as described20 and dissolved in DMSO for in vitro
study. Catalase, dicoumarol, and FTY720 were purchased from Sigma-Aldrich.
OT-1 peptide and OVA protein were from ThermoFisher. Anti-CD4 (GK1.5), anti-
CSF1R (AFS98), anti-IFNAR1 (MAR1-5A3), anti-PD-L1 (10F.9G2), anti-CD8
(YTS), and anti-HMGB1 mAbs were purchased from BioXCell.
Sulforhodamine B (SRB) cytotoxicity assay. Four thousand cells were planted in
a 96- or 48-well plate with triplicates. After overnight growth, cells were exposed to
β-lapachone with or without NQO1 inhibitor dicoumarol (50 μM) for a 3-h pulse.
After that, the cell supernatant was replaced by fresh medium, and the plate was
incubated at 37 °C in a humidiﬁed incubator with 5% CO2 for another 2 or 4 days.
Following treatment, the culture supernatant was removed, and ﬁxative reagents
were gently added to each well. The wells were washed with water and the plate was
air dried overnight. 100 μL SRB Dye solution was added and incubated for 30 min,
followed by washing and air dry. The cell growth was determined by the absor-
bance at 560 nM in a microplate reader (SpectroSTAR Nano, BMG labtech). % Cell
growth= (100 × (cell control−experimental)) ÷ (cell control).
NQO1 knockout and overexpression. NQO1 gene in MC38 cells was knocked out
by CRISPR/Cas9 technology. The guide sequence 5′-TTGTGTTCGGCCACAA
TATC-3′ was cloned into pSpCas9 (BB)-2A-Puro plasmid (Addgene, # 62988)
containing a puromycin selection gene. The plasmid was transiently transfected
into MC38 cells. Forty-eight hours after transfection, puromysin-resistant cells
were selected and subcloned under the selective culture medium. MC38 Cell clones
(#1, #2, and #5) without NQO1 expression were used for in vitro and in vivo
studies. For NQO1 overexpression, B16 cells (NQO1 null) was transiently trans-
fected with a full-length mouse NQO1 protein expression vector pCMV3-HA-
NQO1 (Sino Biological, #MG57522-CY). The NQO1 stable expressing cells were
selected and subcloned under the hygromycin containing culture medium. B16
cells clones (#1, #3 and #4) with NQO1 stable expression were used for following
studies. The NQO1 expression levels were determined by western blotting assay.
Tumor growth and treatment. Approximately 6 × 105 MC38 cells or 1.5 × 105
TC-1, or 1.5 × 105 B16 cells were subcutaneously inoculated into the right ﬂank of
mice. Tumor-bearing mice were randomly grouped into treatment groups when
tumors grew to certain sizes. For β-lap monotherapy, tumor-bearing mice were
treated with β-lap locally (intratumorally, 1.5, 5, or 15 mg/kg every other day for
four times) or systemically (intravenously or intraperitoneally, 25 or 30 mg/kg
every other day for four or six times). For CD4 and CD8+ T cell depletion, 200 μg
of antibodies were intraperitoneally injected four times at three days interval. For
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mMcrophage depletion, 100 μg of Anti-CSF1R mAb were intratumorally injected
three times at 3 days interval during β-lap treatment. For type I IFN blockade
experiment, 150 μg of anti-IFNAR1-blocking mAbs were intratumorally injected at
3 days interval for a total three times. The blocking and depletion experiments
above started one day before the ﬁrst β-lap treatment. For HMGB1 blockade
experiments, 200 μg of anti-HMGB1 mAbs were administered intraperitoneally
(i.p.) every 3 days for total three times staring at the same day of the ﬁrst β-lap
treatment. For PD-L1 checkpoint blockade combination therapy, 100 μg (for the
MC38 model) or 150 μg anti-PD-L1 (for the B16 model) was administered intra-
peritoneally to tumor-bearing mice every 3 days for total three times starting at the
same day of the ﬁrst β-lap treatment. Tumor volumes were measured at least twice
weekly and calculated as 0.5 × length × width × height. The “Spaghetti plots” of
each tumor growth curve of individual mouse for in vivo study are shown in
Supplementary Fig. 10.
Immune-reconstituted mouse models. For C57BL/6 Rag1−/− immune-
reconstituted model, 2 × 106 A549 cells were s.c. inoculated into female Rag1−/−
mice. After the tumor was well established (about 100 mm3), 2 × 106 total LN cells
from OTI transgenic mice were intravenously injected into the tumor-bearing
mice one day before treatment. Later, the mice were treated with β-lap locally (i.t.,
10 mg/kg) every other day for four times. Tumor volumes were measured at least
twice weekly.
For NSG-SGM3 humanized mouse model, four-week-old NSG-SGM3 female
mice were irradiated with 100 cGy (X-ray irradiation with X-RAD 320 irradiator)
one day prior to human CD34+ cells transfer. Irradiated mice were treated with
Bactrim (Aurora Pharmaceutical LLC) water for 2 weeks. Cord blood was obtained
from UT Southwestern Parkland Hospital. Human CD34+ cells were puriﬁed from
cord blood by density gradient centrifugation (Ficoll® Paque Plus, GE healthcare)
followed by positive immunomagnetic selection with anti-human CD34
microbeads (Stem Cell). 1 × 105 CD34+ cells were intravenously injected into each
recipient mouse. Eleven weeks after engraftment, humanized mice with over 60 %
human CD45+ cells reconstitution and age and sex matched non-humanized mice
were inoculated with 3 × 106 A549 tumor cells subcutaneously on the right ﬂank.
At day 19, the tumor-bearing mice were treated with β-lap locally (i.t., 10 mg/kg)
every other day for four times. Tumor volumes were measured at least twice
weekly. All experiments were performed in compliance with UTSW Human
Investigation Committee protocol and UTSW Institutional Animal Care and Use
Committee.
HMGB1 release detection. Tumor cells were planted in a six-well plate and grown
to 70% conﬂuence and treated with increasing concentration of β-lap for 3 h,
followed by washing and medium replacement. The supernatant was assayed for
extracellular HMGB1 24 h later using an ELISA KIT (Chondrex).
IFNγ enzyme-linked immunosorbent spot assay (ELISPOT). Tumor drain LNs
and spleen from tumor-bearing mice were collected and single-cell suspension was
prepared. Irradiated tumor cells or OT-1 peptides were used to re-stimulate the
tumor-speciﬁc T cells. In general, a total of 2–4 × 105 LN cells or splenocytes and
2–4 × 105 irradiated tumor cells were co-cultured for 48 h, and ELISPOT assay was
performed using the IFNγ ELISPOT kit (BD Bioscience) according to the manu-
facturer’s instructions. Spots were calculated by an ImmunoSpot Analyzer (Cellular
Technology Limited).
Cell isolation from tissues. CD11c+ DCs or CD8+ T cells were isolated from
lymph nodes or spleen of mice with a positive CD11c isolation kit or a negative
CD8 isolation kit (Stemcell) according to the manufacturer’s instructions. For
tumor single-cell suspension, tumor tissues were cut into small pieces, and
resuspended in digestive buffer (1.5 mg/ml type I collagenase and 100 μg/ml DNase
I) for 45 min in a 37 °C shaking incubator. After digestion, cells were passed
through a 70-μm cell strainer.
Flow cytometric analysis. Tumor cell suspension was blocked with the anti-
CD16/32 antibody (clone 2.4G2) for 10 min, and then incubated with indicated
antibody for 30 min at 4 °C in the dark. Fixable viability Dye eFlour 506
(eBioscience) was used to exclude the dead cells. Sample was analyzed on a
CytoFLEX (Backman coulter) ﬂow cytometer. An example of gating schematics
was shown in supplementary Fig. 11 to characterize the immune cell inﬁltrates in
tumor tissue. Antibodies used in this study had been listed in the Supplementary
Table S1.
DCFDA cellular ROS detection assay. The level of cellular ROS was determined
by the DCFDA-Cellular ROS Detection Assay Kit (Abcam) according to the
manufacturer’s instructions. Brieﬂy, cells were plated into 12-well plates and grown
to about 70% conﬂuence, and stained with DCFDA at 37 °C for 30 min. After that
cells were treated with different concentration of β-lap for 3 h. ROS signal was
determined using Flow cytometry at Ex/Em: 485/535 nm.
Quantitative real-time PCR. Total RNA from cells was extracted with the TRIzol
(Invitrogen) and reversed-transcribed with iScript™ gDNA Clear cDNA Synthesis
Kit (Bio-Rad). Real-time PCR was performed with SsoAdvanced™ Universal SYBR®
Green Supermix (Bio-Rad) according to the manufacturer’s instructions. Primers
used in this study are listed in the Supplementary Table 2. β-Actin was used as the
internal control. 2−ΔΔCt method was used to calculate relative expression changes.
Statistical analysis. All the data analyses were performed with GraphPad Prism
statistical software and shown as mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001
and ****p < 0.0001 determined by two-way ANOVA or unpaired two-tailed t-tests.
A value of p < 0.05 was considered statistically signiﬁcant.
Reporting Summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The source data for the in vivo studies underlying Figs. 1–6 and Supplementary Figs. 1–8
are provided as a Source Data ﬁle. All the other data supporting the ﬁndings of this study
are available within the article and its supplementary information ﬁles and from the
corresponding author upon reasonable request. A reporting summary for this article is
available as a Supplementary Information ﬁle.
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